Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people need to take Wegovy long-term to maintain the weight loss it produces. Clinical evidence shows that the majority of weight lost during treatment is regained within a year or two of stopping, because semaglutide works by actively altering appetite signals — signals that return to their previous state when the medicine leaves your system. That said, whether you personally need to stay on it indefinitely is a clinical decision, not a foregone conclusion. These are prescription-only medicines assessed individually, and a prescriber weighs your health picture, your goals and how your body has responded before any long-term plan is made.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy contains semaglutide, a GLP-1 receptor agonist that works by mimicking a gut hormone your body already produces after eating. It slows gastric emptying, reduces appetite signalling in the brain and helps you feel full on less food. The result, for most people, is a significant reduction in calorie intake without the conscious effort of restriction. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose.
Crucially, none of that is permanent reprogramming. The medicine is managing a biological tendency, in much the same way that blood-pressure medication manages pressure while you take it. Stop taking it, and the physiology it was modulating gradually reverts. That is not a flaw in the medicine, it is how the pharmacology works, and being clear-eyed about it helps you plan.
You can read more about how semaglutide works on our semaglutide overview page.
The clearest evidence on this question comes from the STEP 4 trial. Participants who had lost weight on semaglutide were then randomly assigned either to continue or to switch to placebo. Those who stopped regained, on average, about two-thirds of their lost weight within a year. Appetite returned. The biological signals that had been dampened reasserted themselves.
This pattern is not unique to Wegovy. It reflects a broader truth about obesity as a chronic condition: the physiological drivers of weight gain do not disappear because weight has been lost. The NHS England guidance on weight-management injections addresses long-term use directly and frames these medicines within a broader, ongoing clinical relationship rather than a fixed course.
There is also a related question our prescribers are asked regularly: can you take Wegovy forever if it keeps working? The honest answer is that the safety data out to several years is reassuring, and for people with significant weight-related health conditions, the benefits of continuing often substantially outweigh the risks of stopping. That conversation belongs with a prescriber who knows your full history. If you are already on treatment and wondering about the long term, our guide to staying on Wegovy long-term goes deeper into that question.
It would be misleading to say that everyone who stops regains everything. Some people do sustain a meaningful proportion of their weight loss, and researchers have tried to identify what separates them from those who regain quickly. The pattern that emerges is unsurprising in retrospect: the people who fare best after stopping are those who have used the period on treatment to build genuinely different habits around eating, activity and sleep, not as a willpower exercise, but because reduced appetite made those changes easier to establish and sustain.
If you are thinking about this now (part-way through treatment or considering starting) the practical implication is to treat the suppressed-appetite window as time to consolidate, not to coast. The weight-loss treatment overview on this site covers the lifestyle component that runs alongside medication.
It is also worth knowing that NICE's recommendation for semaglutide (Wegovy) under TA875 specifies a maximum treatment duration of two years within NHS specialist services, which is partly a resource decision and partly a recognition that the long-term evidence base is still maturing. Private treatment is not subject to that cap, but questions about whether you have to take Wegovy forever are something every patient and prescriber should discuss openly from the start.
We know that for many people reading this, the question feels loaded. You may have lost a significant amount of weight and feel something between gratitude and anxiety about what happens next. That is an entirely reasonable place to be. The prospect of taking a medicine indefinitely is not trivial, financially or otherwise.
What a good prescriber does (and what our team does at every clinical review) is look at the whole picture: how much weight you have lost, which health markers have improved, what your current dose is, how you are tolerating it, and what your own priorities are. The answer for someone who has resolved obstructive sleep apnoea and brought their blood pressure into a healthy range may be different from the answer for someone who is still at the start of their journey, and our guidance on Wegovy for seniors explores how those considerations can shift further depending on age and health profile. There is no single right answer that applies to everyone.
If cost is part of the question (and it often is, particularly for long-term use) our guide to accessing Wegovy through a regulated pharmacy covers what legitimate pricing looks like and what a transparent service includes. For a broader sense of your options, including newer medicines, the treatment consultation page is where that conversation with our prescribers begins.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.